Mallinckrodt stock tumbles after new Citron Research report targets $40,000-a-vial drug

The short-seller claimed a recent development could send Mallinckrodt shares to zero and make the company bankrupt.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.